Relationship between vasopressin and opioids in hypoxia induced pial artery vasodilation.
It has been observed that a vasopressin receptor antagonist attenuates hypoxic hyperemia in fetal sheep, whereas methionine enkephalin (Met) and leucine enkephalin (Leu) contribute to hypoxia-induced pial artery dilation in newborn pigs. This study was designed to investigate the relationship between vasopressin and opioids in hypoxia-induced pial artery dilation in the newborn pig by use of the closed cranial window technique. Hypoxia-induced pial artery dilation was attenuated during moderate [arterial Po2 (PaO2) approximately 35 mmHg] and severe hypoxia (PaO2 approximately 25 mmHg) by the vasopressin receptor antagonist, [beta-mercapto-beta beta-cyclopentamethylenepropionyl, 2-O-Me-Tyr2, Arg8]vasopressin (MeAVP, 5 micrograms/kg i.v.; 29 +/- 1 vs. 14 +/- 2 and 37 +/- 2 vs. 18 +/- 2% for moderate and severe hypoxia in absence vs. presence of MeAVP, respectively, n = 7). Hypoxia-induced dilation was accompanied by increased cerebrospinal fluid (CSF) vasopressin concentration (26 +/- 1 vs. 67 +/- 4 and 26 +/- 1 vs. 99 +/- 4 pg/ml for control vs. moderate and control vs. severe hypoxia, n = 5). Vasopressin increased CSF Met (895 +/- 28, 1,147 +/- 63, 1,327 +/- 48, and 1,600 +/- 75 pg/ml for control and 40, 400, and 4,000 pg/ml vasopressin, respectively, n = 7). CSF Leu concentration was similarly increased by vasopressin. Furthermore, MeAVP attenuated the release of Met during moderate hypoxia (910 +/- 38 and 2,682 +/- 49 vs. 911 +/- 38 and 2,110 +/- 84 pg/ml for control and moderate hypoxia in absence and presence of MeAVP, respectively, n = 5). MeAVP had similar effects on hypoxia-induced Leu release. These data show that vasopressin contributes to hypoxia-induced pial artery dilation and that vasopressin increases CSF Met and Leu concentrations. These data also suggest that elevated CSF vasopressin concentrations that occur during hypoxemia result in opioid release, which subsequently contributes to hypoxic pial artery dilation.
Rossberg
M I
MI
Department of Anesthesia, University of Pennsylvania, Philadelphia, USA.
Armstead
W M
WM
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives / Q000494:pharmacology; D002536:Cerebral Arteries / Q000503:physiopathology; D002851:Chromatography, High Pressure Liquid; D004743:Enkephalin, Leucine / Q000134:cerebrospinal fluid; D004744:Enkephalin, Methionine / Q000134:cerebrospinal fluid; D004745:Enkephalins / Q000134:cerebrospinal fluid*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D000860:Hypoxia / Q000134:cerebrospinal fluid* / Q000503:physiopathology*; D008297:Male; D009994:Osmolar Concentration; D010841:Pia Mater / Q000098:blood supply*; D011863:Radioimmunoassay; D014664:Vasodilation / Q000187:drug effects; D014667:Vasopressins / Q000134:cerebrospinal fluid* / Q000494:pharmacology
D004745:Enkephalins; D006727:Hormone Antagonists; D014667:Vasopressins; D001127:Arginine Vasopressin; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-